News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
115,137 Results
Type
Article (8697)
Company Profile (43)
Press Release (106397)
Section
Business (32251)
Career Advice (149)
Deals (4740)
Drug Delivery (31)
Drug Development (19452)
Employer Resources (13)
FDA (4035)
Job Trends (2586)
News (61281)
Policy (7194)
Tag
Academia (535)
Allergies (20)
Alliances (10236)
Alzheimer's disease (244)
Antibody-drug conjugate (ADC) (23)
Approvals (4010)
Artificial intelligence (22)
Bankruptcy (24)
Best Places to Work (2201)
Biosimilars (53)
Biotechnology (30)
Breast cancer (23)
Cancer (224)
Career advice (129)
Cell therapy (55)
Clinical research (15547)
Collaboration (82)
Compensation (17)
COVID-19 (559)
C-suite (24)
Data (220)
Diabetes (20)
Diagnostics (593)
Drug pricing (15)
Duchenne muscular dystrophy (15)
Earnings (10768)
Events (14710)
Executive appointments (38)
FDA (4187)
Funding (61)
Gene therapy (49)
GLP-1 (111)
Government (1383)
Healthcare (2892)
Immunology and inflammation (19)
Infectious disease (575)
Inflammatory bowel disease (42)
Interviews (19)
IPO (2126)
Job creations (437)
Job search strategy (120)
Layoffs (52)
Legal (739)
Lung cancer (50)
Manufacturing (64)
Medical device (1884)
Medtech (1885)
Mergers & acquisitions (2648)
Metabolic disorders (51)
Neuroscience (286)
NextGen Class of 2024 (875)
Non-profit (478)
Northern California (280)
Obesity (23)
Opinion (44)
Peanut (18)
People (9031)
Phase I (4906)
Phase II (6506)
Phase III (5663)
Pipeline (69)
Policy (27)
Postmarket research (501)
Preclinical (1909)
Press Release (66)
Radiopharmaceuticals (51)
Rare diseases (42)
Real estate (1005)
Regulatory (5495)
Research institute (541)
Southern California (274)
Startups (669)
United States (2505)
Vaccines (145)
Date
Today (19)
Last 7 days (154)
Last 30 days (555)
Last 365 days (7887)
2024 (6681)
2023 (8469)
2022 (11359)
2021 (11719)
2020 (10141)
2019 (7442)
2018 (5802)
2017 (6446)
2016 (5876)
2015 (6741)
2014 (4774)
2013 (3767)
2012 (3889)
2011 (4149)
2010 (3394)
Location
Africa (111)
Asia (8950)
Australia (1112)
California (635)
Canada (166)
China (84)
Colorado (21)
Delaware (17)
Europe (16685)
Florida (96)
Illinois (50)
Indiana (29)
Maryland (217)
Massachusetts (421)
Michigan (16)
Minnesota (39)
New Jersey (272)
New York (188)
North Carolina (151)
Northern California (280)
Ohio (35)
Pennsylvania (117)
South America (163)
Southern California (274)
Texas (67)
Washington State (49)
115,137 Results for "bone biologics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Genetown
First Two Patients Treated in Pilot Clinical Study with Bone Biologics’ NB1 Bone Graft Device in Spine Fusion
Bone Biologics Corporation announces that the first two patients have been treated in the multicenter, prospective, randomized pilot clinical study of the Company’s NB1 bone graft device.
June 20, 2024
·
5 min read
Genetown
Bone Biologics Reports Progress With NB1 Clinical Program
Bone Biologics Corporation, a developer of orthobiologic products for spine fusion markets, reports progress with advancing its product candidate NB1 into human clinical testing for spinal fusion.
March 1, 2024
·
3 min read
Deals
Bone Biologics Announces Pricing of $2.0 Million Public Offering
Bone Biologics Corporation today announced the pricing of its public offering of an aggregate of 781,251 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 781,251 shares of common stock.
March 4, 2024
·
4 min read
Genetown
Bone Biologics Announces Closing of $2.0 Million Public Offering
Bone Biologics Corporation announced the closing of its previously announced public offering of an aggregate of 781,251 shares of its common stock and warrants to purchase up to 781,251 shares of common stock, at a public offering price of $2.56 per share and accompanying warrant.
March 6, 2024
·
3 min read
Press Releases
Novadip reports promising interim results from its first-in-human proof-of-concept trial with NVDX3, a new game changer in the bone field
At six months post-grafting surgery with NVDX3, x-rays demonstrate that 90% of patients have reached, or are steadily progressing towards, complete bone healing Derived from Novadip’s 3M3 stem cell platform, NVDX3, a unique ‘off-the-shelf allogeneic matrix product to cure common but challenging orthopedic conditions, has potential to replace existing allogeneic bone substitutes to heal fractures
October 18, 2024
·
1 min read
Business
Bone Biologics Appoints Healthcare Finance Veteran Robert E. Gagnon to Board of Directors
Bone Biologics Corporation today announced that effective immediately Robert E. Gagnon has been named to the Company’s board of directors.
January 11, 2024
·
3 min read
Deals
Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements
Bone Biologics Corporation today announced that it has received notice from The NASDAQ Stock Market LLC (Nasdaq) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market.
January 10, 2024
·
1 min read
Genetown
Bone Biologics Announces 1-for-8 Reverse Stock Split
Bone Biologics Corporation, a developer of orthobiologic products for spine fusion markets, announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-8.
December 18, 2023
·
3 min read
Genetown
Bone Biologics Provides Scientific Update on NB1 Bone Graft Device
Bone Biologics Corporation (NASDAQ: BBLG) , a developer of orthobiologic products for spine fusion markets, provides an update on its clinical development initiatives with its NB1 bone graft device.
September 26, 2023
·
6 min read
Biotech Beach
Biogennix Announces Publication of a Scientific Study on Its Advanced Bone Graft Technology
Biogennix, an osteobiologics company specializing in products for bone graft procedures, has announced the publication of a detailed scientific study characterizing multiple advanced properties of its TrelCor bone graft material.
June 12, 2024
·
2 min read
1 of 11,514
Next